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Thesis describes a project that starts from evaluation of simulation programs and ends to 
testing an individually adaptive glucose regulatory system (GRS) model. Thesis 
presents a modern adaptive approach to model GRS in order to describe each diabetic’s 
individual causalities. Thesis is divided into three parts; a literature study of diabetes 
and GRS models, analysis of simulation programs, and building dynamics GRS model 
and validating it with clinical data.  
Validation consists literature data for general GRS model and test data from a pilot 
diabetic who underwent two-week study period. Data collected included glucose values 
from two continuous glucose monitors (CGM), fingertip blood glucose measurements, 
meals and exercises. Adaptive parameter identification was applied to the model during 
6 days training period and then blood glucose was estimated for the next 24 hours.  
First part of results show that from four simulation programs analyzed, Simulink 
was the software best meeting Quattro Folia’s functional requirements and demanded 
qualities. Therefore, a general GRS model was built with it. Based on literature review, 
the best model and parts of models were combined for one general model which was 
validated to function as in previous studies. Second part of results show that with 
adequate data, blood glucose can be estimated with decent accuracy. Although the 
material only consist data from one diabetic subject, it gives an indication that blood 
glucose could be estimated for others also. However, the precision over population is 
indecisive. 
To conclude, individual diabetic’s GRS and its functions can be described with 
adaptive system dynamic model. The model have multiple possible usages from in silico 
testing to teaching causalities for diabetics or their parents, thus it is useful for research, 
validation and educational purposes. Its value creators are modularity and wide range of 
possible usages. 
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Diplomityö käsittelee nykyaikaista adaptiivista lähestymistä ihmisen 
sokeriaineenvaihdunnan mallintamiseen. Työ on jaettu kolmeen osaan; 
kirjallisuustutkimus diabeteksestä ja sokeriaineenvaihduntamalleista, 
simulointiohjelmien analysointi, ja dynaamisen mallin rakentaminen ja validointi. 
Validointi sisältää niin kirjallisuustietoa kuin myös kliinistä dataa yhdeltä tyypin 1 
diabeetikolta kahden viikon pilottijakson ajalta. Materiaali sisälsi kahden 
sensorimittarin verensokeriarvot, perinteisen verensokerimittarin arvot, ateriatiedot ja 
liikuntatiedot. Viikko jaettiin kahteen osaan, kuusi ensimmäistä päivää parametrien 
identifikointia varten ja seitsemäs päivä tulosten testaukseen. Toisin sanoen 
verensokeria pyrittiin estimoimaan 24 tunnin ajalta edeltävän kuuden päivän perusteella. 
 Ensimmäinen osa tuloksista osoittaa, että neljästä analysoidusta 
simulointiohjelmasta, Simulink oli parhaiten Quattro Folian käyttötarkoituksia ja 
vaatimuksia vastaava. Näin ollen mallinnus tehtiin edellä mainitulla ohjelmalla. 
Kirjallisuuskatsauksen perusteella valittu yleinen sokeriaineenvaihdunta malli ja mallien 
osia yhdistettiin kokonaisuudeksi, joka validointiin toimivan fysiologisesti oikein.  
 Tulokset osoittivat, että riittävällä määrällä yhtenäistä dataa pystytään verensokeria 
estimoimaan kohtuullisella tarkkuudella. Vaikka materiaalina oli vain yhdeltä 
diabeetikolta kerättyä dataa, voidaan olettaa, että koejärjestely on toistettavissa 
onnistuneesti myös muille diabeetikoille. Kuitenkaan estimoinnin tarkkuudesta ei voida 
antaa arvioita.  
 Diabeetikon sokeriaineenvaihduntaa voidaan kuvata dynaamisella mallilla, joka 
adaptoituu yksilön mukaan. Mallia voidaan käyttää esimerkiksi validointiin 
simulointitesteillä, tutkimuksiin  tai diabeetikkojen opetukseeen. Toisin sanoen mallin 
arvo muodostuu sen modulaarisuudesta ja useista eri käyttökohteista. 
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1.    INTRODUCTION 
In year 1980 WHO Expert Committee on Diabetes Mellitus, estimates that 30 million 
people have diabetes [1]. In year 2013, International Diabetes Federation (IDF) 
estimates that there are 382 million people living with diabetes and additional 316 
million people with impaired glucose tolerance. Thus, they are at high risk from the 
disease. In past 30 years the number of diabetics is more than tenfold and by all 
measures, the number has not reached its peak yet. [2, p.7] 
Although diabetes is a widespread and common disease, every individual needs 
unique care. For instance type 1 diabetic person has to decide every time he eats, 
whether to have insulin bolus, how many units the bolus should be, when to take it, will 
I exercise afterwards, etc. In addition, there is also need for basal insulin which 
basically means that in order to keep the blood sugar in balance person will take one or 
two additional injections daily. It has been estimated that a person with type 1 diabetes, 
makes 300 decisions per day that are related to their self-care [3]. Figure 1.1 shows a 
sketch of the balancing equation that diabetic or diabetic parent undergo around-the-
clock. Equation includes elements such as exercise, medication, eating, sleeping, stress, 
etc. Although doctors and nurses advices patients with the care plan, most of the daily 
decisions are more or less done based on the individual's understanding of the disease.  
 
Figure 1.1: The balancing equation that diabetic person is dealing with around-the-clock: 
Blood glucose is measured and insulin is administered. 
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 The aim is to develop an individual model to every patient's glucose regulatory 
system to be used as a tool for learning and understanding. Output for patient can be just 
some simple cause-effect charts or insulin bolus advisor, but doctors can access to all 
the available data to be able to evaluate how the care plan is succeeding and then make 
adjustments if necessary. The model should be suitable at least for both type 1 and type 
2 diabetes. 
 Nowadays technology has already shown a great variety of options to measure 
human body and its functions. Idea is to combine all measurement data and update the 
older glucose regulatory models to respond the modern technology status.  
 To summarize, the number of diabetics is increasing so the need for individual care 
is increasing. Hospitals and clinics are incapable to respond to this growing need and 
therefore modern models can have a significant influence for diabetic to be able 
understand how his or her body functions and for care team to be able to react to 
individual's needs quicker and more efficiently, thus to lead a healthy life with 
minimum amount of complications. 
 Chapter 2 of thesis gives a brief overview to diabetes, GRS models and system 
dynamics. Chapter 3 provides information about materials and methods used in this 
thesis. Chapter 4 presents results of simulation program selection, dynamic GRS model 
and individual GRS model. Chapter 5 analyses the results and conclude the thesis. The 
appendices include further information about parameters and subsystem models build 
with Simulink.  
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2.    THEORETICAL BACKGROUND 
2.1 Diabetes Mellitus  
Diabetes mellitus describes a metabolic disorder of multiple etiologies characterized by 
chronic hyperglycemia with disturbances of metabolism resulting from defects in 
insulin secretion, action, or both [4, p. 2]. Diabetes are generally considered to be 
divided into two main types; type 1 and type 2 diabetes mellitus. 
 
2.1.1 History of Diabetes 
The first known mention of diabetes is from 1552 BCE, when Egyptian physician Hesy-
Ra listed remedies to 'passing of too much urine'. The next and more completing 
description of diabetes was given by Greek physician Aretaes of Cappodocia. He 
referred diabetes as 'melting down of flesh and limbs into urine'. [5] In the 17th century 
Dr. Thomas Willis discovered that diabetes can be diagnosed by sampling urine. 
Sampling was done by tasting the urine and estimating the sweetness of it, but still it 
took almost 300 years to discover at least somewhat efficient treatment for diabetes and 
in the early 20th century, Dr. Frederick Allen prescribed low calories diets for diabetics. 
[6] 
 Insulin was discovered in the early 1920s by Dr. Frederick Banting. He started 
injecting insulin to diabetic dogs and moved on to cattle. Dr. Banting and Charles Best 
with assistance of Prof. John Macleod first tested insulin to themselves and after 
discovering that there is no significant side-effects, they injected 14-year-old diabetic 
boy called Leonard Thompson. He was weak and near death, but with insulin shots he 
managed to regain his strength and appetite. Although insulin will not cure the diabetes, 
it gives the person possibility to live otherwise normal life and, thus, insulin has become 
part of everyday life of each type 1 diabetic. In 1923 Dr. Banting and Prof. Macleod 
were awarded with the Nobel Prize in Physiology or Medicine. After this many studies 
regarding to diabetes has been published and helping devices such as insulin pump has 
been invented. [7] 
2.1.2 Glucose Metabolism 
When human ingest food that includes carbohydrates, glucose is absorbed to blood 
stream via digestion system. Absorption starts already in mouth, but happens mostly in 
guts. The glucose appears in blood circulation as a function of time depending also on 
various factors such as the type of carbohydrate ingested.  
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 Figure 2.1 describes body's causalities. Plasma glucose level controls pancreatic 
actions. Its alpha or beta cells in the islets of Langerhans releases glucagon or insulin, 
respectively, which then are connected via portal vein to liver. If glucose level is high, it 
activates beta cells which triggers insulin secretion that is multi-oscillatory process with 
rapid pulses and slower so called ultradian oscillations. The length of slow pulse is 
about 10 minutes and ultradian pulse varies from 50 to 120 minutes. Insulin controls the 
glucose uptake in muscles and adipose tissue (i.e. fat) and stimulates liver glucose 
storage. [8] 
 
Figure 2.1: Role of pancreas in glucose metabolism [2, p. 27] 
 
If plasma glucose is low, pancreatic response is to release alpha cells that triggers 
glucagon secretion. Glucagon elevates glucose level by binding to receptors on liver and 
therefore activating breakdown of glycogen to glucose. [9, p. 217-220] 
2.1.3 Medical Aspects of Diabetes Mellitus 
 Diabetes has two main types, 1 and 2. First, insulin-dependent type 1 diabetes 
mellitus, usually develops in childhood or in adolescent and is also known as juvenile 
diabetes. It is mainly caused by autoimmune destruction of beta cells of the pancreas. 
Beta cells are the only cells that make the hormone insulin that allows glucose to enter 
the cell, where it is converted into energy. Therefore treatment basically always includes 
lifelong insulin injections in different combinations. There is no cure for diabetes, at 
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least yet, discovered and the key component of the treatment is diabetic himself. His 
daily routine is to act as his own pancreas and, thus, prevent or at least, delay diabetes 
related complications such as hypoglycemia, hyperglycemia, heart disease, kidney 
failure, retinopathy, nerve damage, etc. [9, p. 390-430]. 
 The first symptoms of type 1 diabetes mellitus includes increased frequency of 
urinary, unexplained weight loss, thirst and hunger, all of which are due to too high 
blood glucose level. Pain in feet, numbness in extremities and blurred vision are usual 
symptoms also. Severe symptoms are loss of consciousness or severe nausea or even 
coma. The first assumption is made with mentioned symptoms and it is confirmed 
usually with plasma glucose measurements. If person’s fasting plasma glucose is over 7 
mmol/L, he or she most likely have diabetes. Confirmation is done with oral glucose 
tolerance test (OGTT) that is the most common method to confirm diagnosis of 
diabetes. In OGTT person ingests 75 grams of glucose and blood sugar is measured two 
hours after. If glucose is above 11.1 mmol/L, the original assumption is confirmed and 
person has diabetes. Diagnosis can be also done by measuring person’s glycosylated 
hemoglobin (HbA1c). If HbA1c level is above 6.5 %, person is diagnosed to have 
diabetes. [4, p. 1; 10, p. 37]  
 The most common type of diabetes is type 2. It has been estimated that 80-90% of 
diabetics are type 2 diabetics. It usually occurs in adults due to still unknown reason. 
Though, there are several important risk factors such as obesity, poor diet, physical 
inactivity, family history of diabetes, aging, ethnicity, etc.  [2, p. 23] 
 In type 2 diabetes, a person have insulin secretion, but his cells do not use insulin 
properly. This is called insulin resistance increases. At first, the pancreas secretes more 
insulin in order to get the glucose into the cells. But, eventually the sugar builds up in 
blood stream. Type 2 can develop without any of previously mentioned symptoms of 
type 1 diabetes, but the diagnosis is still done with OGTT or HbA1c measurement. 
Initial treatment for type 2 is fixing person's diet and exercise, but in some cases insulin 
boluses are also need. In addition, person can have prediabetes symptoms: impaired 
glucose tolerance (IGT) or impaired fasting glucose (IFG). These people are at high risk 
of developing type 2 diabetes, but can prevent it with decreasing saturated fat in food, 
losing weight 5-10%, daily exercise, etc. [9, p. 455-457] 
 For type 1 diabetic, treatments first aim is to get enough insulin to cover the basic 
metabolism so that the cells can use glucose as an energy source.  This is done with 
basal insulin that is usually administered once or twice a day depending on insulin. 
Figure 2.2 shows the active time of different insulin types. Detemir and glargine are 
called long-acting insulin and typically used as basal insulin, but also Neutral Protamine 
Hagedorn (NPH) can be used for same purposes. 
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Figure 2.2: Comparison of insulin analog active times [11] 
 
Next aim is to have enough, but not too much, insulin to cover rising plasma glucose 
level after eating. Nowadays the most common insulin for carbohydrate coverage is 
rapid-acting insulin such as Aspart, Lispro, etc.  Meal time bolus is taken usually 10-20 
minutes before eating [12, p. 278-279]. The size of bolus is decided based on the 
individual’s carbohydrate coverage ratio (CHO ratio). It can be calculated as in 
Equations 2-1, which is also known as 'The Rule of 500'.  
𝐶𝐻𝑂 𝑟𝑎𝑡𝑖𝑜 =
500
𝑇𝐷𝐼
              (2-1) 
where TDI is total daily insulin in international units (IU) and 500 is an average 
ingested carbohydrates daily. The meal bolus is then calculated as follows: 
𝑀𝑒𝑎𝑙 𝐵𝑜𝑙𝑢𝑠 =
𝑇𝑜𝑡𝑎𝑙 𝑔𝑟𝑎𝑚𝑠 𝑜𝑓 𝐶𝐻𝑂 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑒𝑎𝑙
𝐶𝐻𝑂 𝑟𝑎𝑡𝑖𝑜
      (2-2) 
In addition to meal bolus, there is a correction bolus. When high plasma glucose is 
measured, sufficient amount of insulin is administered to scale back the high plasma 
glucose level. The size of bolus depends on persons insulin sensitivity factor (ISF). It 
can be calculated with 'The Rule of 1800' as follows: 
𝐼𝑆𝐹 =
1800
𝑇𝐷𝐼
              (2-3) 
The correction bolus is then 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝐵𝑜𝑙𝑢𝑠 =
𝑃𝐺𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑−𝑃𝐺𝑡𝑎𝑟𝑔𝑒𝑡
𝐼𝑆𝐹
        (2-4) 
where PGmeasured the measured plasma glucose level and PGtarget is the target plasma 
glucose level. Note that both plasma glucose units are now in mg/dl. SI units are 
mmol/L and the factor from mmol/L to mg/dl is 1/0.055. [13] 
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 Above described are 'rules of thumb' and not intended to be strictly accurate in 
every situation. Most likely doses need to be modified to meet the individual targets. 
Also, these are only for rapid-acting insulin and more suitable for type 1 diabetics than 
type 2. For instance, dawn phenomenon is something that might have to be taken into 
account when calculating insulin doses. Some persons experience increased plasma 
glucose in mornings, because liver releases glucose for unknown reasons. One 
suggested reason is increased level of growth hormone. Anyhow this means that 
diabetic who experience dawn phenomenon, have to take insulin bolus in morning 
whether he will eat breakfast or not. In addition, the meal related bolus might need to be 
injected earlier than usually. [12, p. 293-294] 
Another example is the blood glucose level’s effect on insulin sensitivity. If blood 
glucose rises above 12-15 mmol/L, person’s insulin sensitivity lowers, thus the person 
needs more insulin in order to lower the glucose level back to target range. [9, p. 92] 
2.1.4 Social and Economic Impact of Diabetes 
In past decades diabetes has grown in numbers and the problem is not only in 
industrialized countries anymore. The economic growth of developing countries have 
led to increasing numbers of diabetics worldwide and Figure 2.3 shows the global scale 
of diabetes. IDF has been estimated that people living with diabetes will increase 55 
percent by the end of year 2035 which sums up to 592 million diabetic. [2, p. 12] 
 In Finland, diabetes mellitus is considered as a national disease. The numbers of 
both type 1 and type 2 diabetes has been growing significantly. From 1997 to 2007 the 
number of type 1 diabetics has grown 18 percent and the number of type 2 diabetics has 
grown alarming 77 percent. Small portion of the grown numbers can be explained by 
increased awareness of disease, thus more persons have been examined to find out if 
they have diabetes. Yet, undiagnosed diabetes is a common problem in Finland and 
worldwide. [14] 
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Figure 2.3: People living with diabetes worldwide [2, p. 11] 
 
 Diabetes imposes a severe burden on national health systems, countries and 
individuals and their families. IDF estimates that in 2013, 10.8 percent of total health 
expenditure worldwide is used to diabetes and all of that is used to treat diabetes not 
prevent it. The amount of money per diabetic has a huge variety depending where 
person lives. For instance Norway spent to diabetes healthcare 8 104 € (USD 10 368) 
per diabetic whereas Somalia and Eritrea spent under 23 € (USD 30). [2, p. 48] 
 
 
Figure 2.4: Social and economic burden of diabetes in Finland 1998-2007 [15] and 
estimated continum for 2008-2024. 
9 
 
 Figure 2.4 shows the distribution of diabetes expenses in Finland from 1998 to 
2024. The largest portions are healthcare and premature retirement expenses that 
includes loss in man-years and paid pensions. Healthcare cost are mostly diabetes 
related secondary diseases due to poor diabetes management. Estimations of expenses 
between 2008 and 2024 is done by linear extrapolation since all four areas had very 
high linear correlations during the retrospective study done by Jarvala et al. Correlations 
were 0.9947, 0.9588, 0.9978 and 0.9850 with expenses of healthcare, premature 
retirement, premature deaths and sick leaves, respectively. In the fit for the cost of 
premature deaths values before 2004 were extracted since the cause of deaths have been 
documented only from 1994 and thus, the increase in the start of study was biased. [15] 
2.2 Literature Review of Glucose Regulatory System Models 
Nowadays diabetes care has progressed towards self-care. Since we all are individuals, 
one of the most influence aspect of the care is understanding how your body functions. 
Even though human is very complex system with many unknown variables, different 
dynamic cause-effect models have been introduced. It has been suggested that modern 
glucose regulatory system (GRS) models can lead to understanding of pathogenesis and 
prediction of diabetes mellitus [16]. 
2.2.1 Minimal Models 
Minimal models show the macro-level responses of the system. Those do not include 
every known substrate or hormone, thus they are insensitive to many micro-level 
relationships [17]. To understand the glucose system, dynamic data are needed. 
Therefore quantitative tracer theories has been studied to identify effect of insulin on 
glucose. Resulting in linear and nonlinear time-variant compartmental models that are 
shown to be accurate and allowing the use of exponential models to understand the 
amount of compartments needed to describe the system. Figure 2.5 shows an example 
of three compartment insulin model from which the compartment 3 controls the basal 
glucose. [18, p. 1057-1059] 
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Figure 2.5: Three compartment basal model by P. Insel et al. First three compartments in 
red are representing the basal insulin model and 6, 7 and 9 in blue the basal glucose 
model. The insulin mass in compartment 3 controls the glucose loss from compartment 
9. Figure is reconstructed from [18, p. 1061]. 
 
Later is shown that compartments 1 and 2 can be combined for a single compartment 
and only a two-compartment model is resolvable after 2-3 minutes of tracer injection 
[19]. 
 Bergman et al. introduced even simpler model in 1979. This model have been used 
in clinics to examine body factors such as insulin sensitivity and pancreatic 
responsiveness; factors that are crucial to understand the etiology of IGT. The problem 
in making independent measurements of above mentioned factors is the glucose-insulin 
dynamics and causality of the IGT. As mentioned before the minimum models leaves 
out feedback loops and therefore it is difficult to hold other aspects of the system 
constants to isolate the effect of these factors. [20; 21] 
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Figure 2.6: Bergman's minimal model 6 that is used to estimate the insulin sensitivity 
from intravenous glucose tolerance test. Figure was reconstructed from [20, p. 671]. 
 
 Bergman's study presents seven different glucose-insulin models. Figure 2.6 shows 
the minimal model which Bergman proved to be the most suitable for estimating the 
plasma glucose concentration by using plasma insulin as the known input. Parameters 
are explained in Table 2.1. Model assumes that the remote insulin controls both net 
hepatic glucose balance and peripheral glucose disposal.  
 
Table 2.1: Symbols and descriptions of variables for Bergman's minimal model shown in 
Figure 2.6 and presented in Equation 2-5-7. 
Symbol Description Units 
G(t) Plasma glucose concentration mg/dl 
X(t) Auxiliary function representing insulin-excitable tissue 
glucose uptake activity: (k4 + k6) * I'(t) 
1/min 
I(t) Insulin concentration μU/ml 
G0 Basal glucose concentration mg/dl 
I0 Basal insulin concentration μU/ml 
p1 Fractional transfer rate:  
-(k1 + k5) 
1/min 
p2 Fractional transfer rate: -k3 1/min 
p3 Fractional transfer rate and conversion factor:  
(k4 + k6) * k2 
1/min2
mU/ml
 
SI Insulin sensitivity index 1/min
μU/ml
 
k1, k2, k3, k4, 
k5, k6 
Constant rate parameters 1/min 
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The equations of glucose disappearance model are as follows: 
𝑑𝐺
𝑑𝑡
= [𝑝1 − 𝑋] ∗ 𝐺(𝑡) − 𝑝1 ∗ 𝐺0          (2-5) 
𝑑𝑋
𝑑𝑡
= 𝑝2𝑋 + 𝑝3𝐼(𝑡)            (2-6) 
where the variables are given in Table 2.1. 
 For individual patient the coefficients of the minimal model are estimates from the 
intravenous glucose tolerance test (IVGTT) data by allowing the model predict the 
observed decrease in plasma glucose when the measured plasma insulin is supplied. 
Insulin sensitivity SI then is calculated as follows: 
 𝑆𝐼 =
𝑝3
𝑝2
               (2-7) 
The unit is 1/minute/µIU/ml. Thus, the increase of fractional renal clearance rate of 
glucose per unit change in the plasma insulin concentration. Although, this approach 
gives a good estimation of the insulin sensitivity, it is too simple to be an adequate 
representation of the glucose-insulin system. First, there is no experimental basis that 
insulin secretion and glucose has a linear relationship. Second, the model does not 
consider explicitly the complex interactive control of liver glucose production. It has 
been shown that the model can give negative values for insulin sensitivity in type 2 
diabetics [22]. 
 In addition, the model can be used also to estimate insulin secretion responsiveness 
to glucose both first phase Φ1 and second phase Φ2 by predicting the time course of 
plasma insulin, when above described method is supplied. The first phase insulin 
release is presented as an insulin bolus entering the plasma compartment at the time of 
glucose injection. The equation is 
𝛷𝐼 =
𝐼0
𝑛∗𝛥𝐺
              (2-8) 
where I0 is the first peak of plasma insulin concentration, n is the time constant for 
insulin disappearance and ΔG is the maximum change in the glucose concentration.  
 The factor Φ2 is defined as second phase pancreatic response and is proportional to 
the degree γ by which glucose exceeds a threshold level h. Thus, insulin secretion can 
be described by  
𝑑𝐼(𝑡)
𝑑𝑡
= 𝛾[𝐺(𝑡) − ℎ] + 𝑛 ∗ 𝐼           (2-9) 
The model assumes that the rate of rise of second phase is proportional to plasma 
glucose, thus the second phase responsiveness Φ2 is the proportionality factor between 
glucose and the rate of rise. This is also known as minimal model of insulin kinetics. 
[21] 
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 Bergman and Cobelli have published papers; completing, testing and validating the 
results of the minimal model [17; 21; 23-26] and in 2009, Cobelli estimated that the 
minimal model can be found in over one thousand studies [17]. The most important 
defect in minimal model appears to be the single-compartment representation of the 
glucose system. According to the American Diabetes Association (ADA) Consensus 
Development Conference on insulin resistance, minimal model method applied to a 
frequently sampled IVGTT is one of only two methods that assess peripheral insulin 
resistance. [27] 
 
2.2.2 Maximal Models 
Maximal models are describing the whole glucose regulatory in human body are not 
generally useful for the quantification of specific metabolic relationships. Their 
usefulness lies on the system simulation. Most of the models are based on the multi-
compartment approach and are challenging to validate against clinical data. 
 One of the first dynamic glucose regulatory models was Foster's glucose 
homeostasis model (Figure 2.7). The purpose of the study was to design and experiment 
new glucose regulatory system in man. It has three subsystems that are plasma glucose, 
muscle glycogen and liver glycogen of which non-linear relationships were collected 
from clinical researches found in literature. [28] 
 The mass balance equation for the model is as follows: 
 
{
 
 
 
 
 
 
 
 
 
 
𝑑𝐺𝐺
𝑑𝑡
= 𝐺𝐿𝑌𝑂 + 𝐼𝑁𝐽 + 𝐷𝐼𝐺 + 𝐿𝑈𝐿𝐴𝐶 + 𝐺𝐿𝑈𝑁𝐸𝑂
−𝐺𝐿𝑌𝑆 −𝑀𝑈 − 𝐴𝑇𝑈 − 𝑁𝑆𝑈 − 𝑅𝐵𝐶𝑈 − 𝑈
𝑑𝐺𝐿𝑈𝐿𝐼𝑉
𝑑𝑡
= 𝐺𝐿𝑌𝑆 − 𝐺𝐿𝑌𝑂 − 𝐺𝐿𝑈𝐵
𝑑𝑃𝐺𝑆
𝑑𝑡
= 𝑀𝑈 − 𝑃𝐸𝐺 −𝑀𝑅𝐿𝐴𝐶
𝑑𝐼
𝑑𝑡
= 𝐼𝑆𝐸𝐶 − 𝐼𝐷𝐸𝐺
𝑑𝐹𝐹𝐴
𝑑𝑡
= 𝐹𝐹𝐴𝑃 − 𝐹𝐹𝐴𝑈
𝑑𝐺
𝑑𝑡
= 𝐺𝑆𝐸𝐶 − 𝐺𝐷𝐸𝐺
     (2-10) 
where the variables can be found in Table 2.2. 
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Table 2.2: Symbols and descriptions of variables for Foster's glucose regulatory system 
model that is shown in Figure 2.7 and presented in Equation 2-10. 
Abbreviation Explanation Unit 
ATU Adipose Tissue Use mg/min 
DIG Uptake of Glucose from Digestion Rate mg/min 
FFA Plasma Free Fatty Acid mg 
FFAP Free Fatty Acid Production Rate mg/min 
FFAU Free Fatty Acid Utilization Rate mg/min 
G Plasma Glucagon µg 
GDEG Glucagon Degradation Rate µg/min 
GG Plasma Glucose mg 
GLULIV Liver Glucose mg 
GLUNEO Gluconeogenesis mg/min 
GLYB Glucose-6-Phospate Catabolism Rate mg/min 
GLYO Hepatic Glucose Release mg/min 
GLYS Hepatic Glucose Phosphorylation mg/min 
GSEC Glucagon Secretion Rate µg/min 
I Plasma Insulin mIU 
IDEG Insulin Degradation Rate mIU/min 
INJ Intravenous Glucose Infusion Rate mg/min 
ISEC Insulin Secretion Rate mIU/min 
LULAC Liver Uptake of Glucose mg/min 
MRLAC Muscle Release of Lactate mg/min 
MU Muscle Glucose Uptake Rate mg/min 
NSU Nervous System Uptake mg/min 
PEG Muscle Utilization of Glucose for Energy mg/min 
PGS Peripheral Glucose mg 
RBC'SU Red Blood Cell Utilization Rate mg/min 
U Urine Spillage of Glucose mg/min 
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Figure 2.7: Foster's glucose homeostasis model [28, p. 41]. Variables can be found in 
Table 2.2. 
 
 Without going too deeply into the model, it can be said that the unique feature of 
model is that all the rates are based on the best estimates available from the literature of 
that era, thus there is no curve-fitting methods used. In addition many of the rates are 
nonlinear. Model can be used to simulate a human in IVGTT. Also, it performed well in 
comparison to prediabetes behavior, thus it allows to study different causalities of 
diabetes. Yet, the model has its down sides. It does not simulate correctly any other 
response to dynamic stimuli besides IVGTT and its usefulness is therefore limited. 
 Where Cobelli, Bergman, Foster, etc. [19, 20, 28] concentrated more to 
compartments and rates between them, Sturis, Li, etc. [29, 31] kept their focus in 
development of mathematical model that considered the time delays and oscillations in 
human body. Purpose of these models was to explain the reasons to ultradian oscillation 
of insulin response, of which are still debated.  
 In 1991 Sturis et al. [29] developed a parsimonious mathematical model including 
the major mechanisms involved in glucose regulatory system. The occurrence of insulin 
and glucose oscillations was found to be dependent on two features: 1.) The time delay 
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of 30-45 minutes for the effect of insulin on glucose production and 2.) A prolonged 
effect of insulin dependent glucose utilization. These two characteristics were included 
in the model, they were able to mimic all the experimental findings such as self-
sustained oscillations during constant glucose infusion, postprandial oscillations and 
increased amplitude of oscillations after increased stimulation of insulin secretion in 
constant frequency. [29] Later Sturis et al. [30] validated some of their simulated 
findings with experiments. For instance, it was shown that oscillatory insulin infusion is 
more efficient in reducing plasma glucose levels than continuous administration. [30] 
 Li's model has two time delays: insulin response to arise of blood glucose level and 
endogenous glucose production in liver. Delays were around 6 minutes and 36 minutes, 
respectively. The results show that both of mentioned delays are necessary for the 
insulin secretion ultradian oscillation sustainment. In addition, results indicates that 
endogenous glucose production and related time delay are insignificant in modeling 
IVGTT. The model can be used to time the insulin injection to the intake of glucose 
which is one of the key factors in successful insulin therapy. [31; 32] 
One can find many good models for one's needs and the list of models could be still 
continued. The most recognized and sophisticated model was developed by Dalla Man 
et al. [33] in 2007. Model simulates glucose-insulin response during meal time and in 
24-hour glucose-insulin profile and it was constructed from different modules as 
described in Figure 2.8. [33] 
 
Figure 2.8: Dalla Man et al. glucose regulatory model describing the relations between 
different subsystems. Glucose related parts are in blue and insulin related in red. Figure 
was reconstructed from [33, p. 1742]. 
 
 First subsystem, gastrointestinal track, describes functions of oral glucose 
absorption. Input to module is an amount of ingested glucose and output is a glucose 
rate of appearance in plasma. This nonlinear model was tested to perform with good 
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precision when comparing the results to actual clinical data. Stomach is modeled with 
two compartments that represent solid and liquid phases, respectively. A single 
compartment approach is used for gut and a constant rate of intestinal absorption. The 
relations of model parameters are in Equation 2-11 and the explanations of parameters 
in Table 2.3. [33; 34] 
{
 
 
 
 
 
 
 
 
 
 
𝑑𝑄𝑠𝑡𝑜(𝑡)
𝑑𝑡
= 𝑄𝑠𝑡𝑜1(𝑡) + 𝑄𝑠𝑡𝑜2(𝑡)
𝑑𝑄𝑠𝑡𝑜1(𝑡)
𝑑𝑡
= −𝑘𝑔𝑟𝑖 ∗ 𝑄𝑠𝑡𝑜1(𝑡) + 𝐷 ∗ 𝑑(𝑡)
𝑑𝑄𝑠𝑡𝑜2(𝑡)
𝑑𝑡
= −𝑘𝑒𝑚𝑝𝑡(𝑄𝑠𝑡𝑜) ∗ 𝑄𝑠𝑡𝑜2(𝑡) + 𝑘𝑔𝑟𝑖 ∗ 𝑄𝑠𝑡𝑜1(𝑡)
𝑘𝑒𝑚𝑝𝑡(𝑄𝑠𝑡𝑜) =  𝑘𝑚𝑎𝑥 +
𝑘𝑚𝑎𝑥−𝑘𝑚𝑖𝑛
2
∗ {
𝑡𝑎𝑛ℎ[𝛼 ∗ (𝑄𝑠𝑡𝑜 − 𝑏 ∗ 𝐷)]
−𝑡𝑎𝑛ℎ[𝛽 ∗ (𝑄𝑠𝑡𝑜 − 𝑑 ∗ 𝐷)] + 2
}
𝑑𝑄𝑔𝑢𝑡(𝑡)
𝑑𝑡
= −𝑘𝑎𝑏𝑠 ∗ 𝑄𝑔𝑢𝑡(𝑡) + 𝑘𝑒𝑚𝑝𝑡(𝑄𝑠𝑡𝑜) ∗ 𝑄𝑠𝑡𝑜2(𝑡)
𝑅𝑎(𝑡) =  
𝑓∗𝑘𝑎𝑏𝑠∗𝑄𝑔𝑢𝑡(𝑡)
𝐵𝑊
     (2-11) 
 The next module describes a glucose system that includes two compartments that 
describes glucose kinetics. Module's inputs are rate of absorption and endogenous 
glucose production. Transfer outputs are utilization and when glucose level is above 
individual threshold limit, renal excretion. Plasma glucose concentration also controls 
liver glucose production and pancreas beta-cell functions i.e. insulin secretion. Glucose 
system is divided to two compartments, plasma and tissue glucose. Endogenous glucose 
production and rate of appearance increases the plasma glucose whereas renal excretion 
and insulin-independent utilization (glucose uptake by brain and erythrocytes) decreases 
it. The tissue glucose compartment is related to glucose uptake by muscles and adipose 
tissue that is controlled with insulin concentration. Between above mentioned two 
compartments is transfer in both ways depending on individual parameters.   
 The balance equations are as follows: 
{
 
 
 
 
𝑑𝐺𝑝(𝑡)
𝑑𝑡
= 𝐸𝐺𝑃(𝑡) + 𝑅𝑎(𝑡) − 𝑈𝑖𝑖(𝑡) − 𝐸(𝑡) − 𝑘1 ∗ 𝐺𝑝(𝑡) + 𝑘2 ∗ 𝐺𝑡(𝑡)
𝑑𝐺𝑡(𝑡)
𝑑𝑡
= −𝑈𝑖𝑑(𝑡) + 𝑘1 ∗ 𝐺𝑝(𝑡) − 𝑘2 ∗ 𝐺𝑡(𝑡)
𝐺(𝑡) =
𝐺𝑝
𝑉𝐺
  (2-12) 
where parameters are explained in Table 2.3. 
 Glucose utilization can be divided in two part: insulin-dependent and -independent 
utilization. Insulin-independent means the part of glucose body needs to keep vital 
functions going. This basically is constant uptake by brain and erythrocytes. Insulin-
dependent glucose is described with Michelis-Menten nonlinear relation as presented by 
Yki-Jarvinen et al. [35]. Dalla Man et al. obtained similar results which led to following 
equation: 
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{
 
 
 
 𝑈𝑖𝑑(𝑡) =
𝑉𝑀(𝑋(𝑡))∗𝐺𝑡(𝑡)
𝐾𝑀(𝑋(𝑡))+𝐺𝑡(𝑡)
𝑉𝑀(𝑋(𝑡)) =  𝑉𝑚0 + 𝑉𝑚𝑥 ∗ 𝑋(𝑡)
𝐾𝑀(𝑋(𝑡)) =  𝐾𝑚0 + 𝐾𝑚𝑥 ∗ 𝑋(𝑡)
𝑑𝑋(𝑡)
𝑑𝑡
= −𝑝2𝑈 ∗ 𝑋(𝑡) + 𝑝2𝑈 ∗ (𝐼(𝑡) − 𝐼𝑏)
       (2-13) 
where parameters are explained in Table 2.3. Although, when fitting on clinical data 
Kmx collapsed to zero, thus Km was not dependent from X any more. 
 When plasma glucose level exceeds an individual threshold, excretion occurs in 
kidneys. Process is linearly related with plasma glucose and are modeled as follows: 
𝐸(𝑡) = {
𝑘𝑒1 ∗ (𝐺𝑝(𝑡) − 𝑘𝑒2)          𝑖𝑓 𝐺𝑝(𝑡) > 𝑘𝑒2
0                                             𝑖𝑓 𝐺𝑝(𝑡) ≤ 𝑘𝑒2
       (2-14) 
where parameters are explained in Table 2.3. 
 Endogenous glucose production happens in liver compartment that is controlled by 
plasma glucose, plasma insulin and portal vein insulin. Plasma glucose signal and portal 
vein insulin are direct signals, whereas plasma insulin is delayed. Relations are 
described as follows: 
{
 
 
𝐸𝐺𝑃(𝑡) = 𝑘𝑝1 − 𝑘𝑝2 ∗ 𝐺𝑝(𝑡) − 𝑘𝑝3 ∗ 𝐼𝑑 − 𝑘𝑝4 ∗ 𝐼𝑝𝑜(𝑡)
𝑑𝐼1(𝑡)
𝑑𝑡
= −𝑘𝑖 ∗ (𝐼1(𝑡) − 𝐼(𝑡))
𝑑𝐼𝑑(𝑡)
𝑑𝑡
= −𝑘𝑖 ∗ (𝐼𝑑(𝑡) − 𝐼1(𝑡))
    (2-15) 
where parameters are explained in Table 2.3. [33] 
 Insulin is released from the islets of Langerhans in two phases. The first phase is 
controlled by plasma glucose levels. Both high plasma glucose concentration and fast 
increase of plasma glucose trigger the first phase release. Second release is glucose-
independent slow release of newly formed vesicles. This two phase insulin secretion is 
modeled as follows: 
{
 
 
 
 
𝑆(𝑡) = 𝛾 ∗ 𝐼𝑝𝑜(𝑡)
𝑑𝐼𝑝𝑜(𝑡)
𝑑𝑡
= −𝛾 ∗ 𝐼𝑝𝑜(𝑡) + 𝑆𝑝𝑜(𝑡)
𝑆𝑝𝑜(𝑡) = {
𝑌(𝑡) + 𝐾 ∗
𝑑𝐺(𝑡)
𝑑𝑡
+ 𝑆𝑏        𝑖𝑓 
𝑑𝐺(𝑡)
𝑑𝑡
> 0
𝑌(𝑡) + 𝑆𝑏                             𝑖𝑓 
𝑑𝐺(𝑡)
𝑑𝑡
≤ 0
     (2-16) 
and 
𝑑𝑌(𝑡)
𝑑𝑡
= {
−𝛼𝑠 ∗ [𝑌(𝑡) − 𝛽𝑠 ∗ (𝐺(𝑡) − ℎ)]       𝑖𝑓 𝛽 ∗ (𝐺(𝑡) − ℎ) ≥ −𝑆𝑏
−𝛼𝑠 ∗ [𝑌(𝑡) − 𝑆𝑏]                                𝑖𝑓 𝛽 ∗ (𝐺(𝑡) − ℎ) < −𝑆𝑏
  (2-17) 
where parameters are explained in Table 2.3. [36; 37] 
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 Secreted insulin flows from pancreas through portal vein, from which liver 
separates most of the insulin. In humans, 80 percent of insulin is extracted during the 
first liver passage and in addition, the mass of secreted insulin pulse controls the hepatic 
clearance of insulin [38]. Insulin subsystem is modeled similar two compartment model 
than glucose. First compartment is to describe liver related actions and second 
compartment to describe plasma actions. These equations are as follows: 
{
 
 
 
 
𝑑𝐼𝑝(𝑡)
𝑑𝑡
= −(𝑚1 +𝑚3(𝑡)) ∗ 𝐼𝑙(𝑡) + 𝑚2 ∗ 𝐼𝑝(𝑡) + 𝑆(𝑡)
𝑑𝐼𝑝(𝑡)
𝑑𝑡
= −(𝑚2 +𝑚4) ∗ 𝐼𝑝(𝑡) + 𝑚1 ∗ 𝐼𝑙(𝑡)
𝐼(𝑡) =
𝐼𝑝
𝑉𝐼
     (2-18) 
where parameter m3 is  
{
𝑚3(𝑡) =
𝐻𝐸(𝑡)∗𝑚1
1−𝐻𝐸(𝑡)
𝐻𝐸(𝑡) = −𝑚5 ∗ 𝑆(𝑡) + 𝑚6
           (2-19) 
and other parameters are explained in Table 2.3. [33] 
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Table 2.3: Explained parameters of Dalla Man et al. healthy state simulator. Time-varying 
parameters are bolded. 
Subsystem Variable Unit Explanation 
Gastrointestinal 
Track 
D mg Ingested glucose 
Ra mg/kg/min Glucose rate of appearance in plasma 
Qsto mg Total glucose mass in stomach 
Qsto1 mg Glucose mass in liquid phase 
Qsto2 mg Glucose mass in liquid phase 
Qgut mg Glucose mass in intestines 
BW kg Body weight 
kmax 1/min Maximum emptying rate 
kmin 1/min Minimum emptying rate 
kabs 1/min Intestinal absorption rate 
kgri 1/min Grinding rate 
f unitless Fraction of intestinal absorption which 
actually happens 
α 1/mg Rate to minimum 
b unitless Percentage of dose for which k_empt 
decreases 
β 1/mg Rate to maximum 
d unitless Percentage of dose for which k_empt 
increases 
kempt 1/min Gastric emptying rate 
Glucose System 
Gp mg/kg Glucose mass in plasma and rapidly 
equilibrating tissues 
Gt mg/kg Glucose mass in slowly equilibrating 
tissues 
Vg dl/kg Volume of glucose 
k1 1/min Rate parameter 
k2 1/min Rate parameter 
Uii mg/kg/min Insulin-independent utilization 
Fcns mg/kg/min Glucose uptake by brain and 
erythrocytes 
Muscle and Adipose 
Tissue 
Uid mg/kg/min Insulin-dependent utilization 
X pmol/L Remote insulin in interstitial fluid 
Vm mg/kg/min Transport rate 
Vmx mg/kg/min / 
pmol/L 
Maximum transport rate 
Km mg/kg Michaelis constant for glucose disposal 
Kmx mg/kg / pmol/L Maximum for Michaelis constant, thus 
peripheral insulin sensitivity 
p2u 1/min Rate of insulin action on the peripheral 
glucose utilization 
Ib pmol/L Plasma insulin in basal state 
Kidney 
E mg/kg/min Renal excretion 
ke1 1/min Glumerular filtration rate 
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Subsystem Variable Unit Explanation 
ke2 mg/kg Renal threshold of glucose 
Liver 
EGP mg/kg/min Endogenous glucose production 
Id pmol/L Delayed insulin signal 
I1 pmol/L First insulin signal 
Ipo mg/kg Amount of insulin in portal vein 
kp1 mg/kg/min Extrapolated EGP at zero glucose 
kp2 1/min Liver glucose effectiveness 
kp3 mg/kg/min / 
pmol/L 
Parameter governing amplitude of 
insulin action, thus hepatic insulin 
sensitivity 
kp4 mg/kg/min / 
pmol/kg 
Parameter governing amplitude of 
portal insulin action 
ki 1/min Rate parameter 
Beta-cell 
S pmol/kg/min Insulin secretion 
γ 1/min Transfer rate between portal vein and 
liver 
Y pmol/kg/min Secretion because of high plasma 
glucose 
K pmol/kg / mg/dl Pancreatic responsivity to glucose rate 
of change 
Sb pmol/kg/min Secretion in basal state 
α_s pmol/kg/min / 
mg/dl 
Delay between plasma glucose and 
insulin secretion 
β_s 1/min Pancreatic responsivity to glucose 
h mg/dl Threshold level of glucose above beta 
cells initiate to produce new insulin 
Insulin System 
Ip pmol/kg Insulin mass in plasma 
Il pmol/kg Insulin mass in liver 
m1 1/min Rate parameter 
m2 1/min Rate parameter 
m3 1/min Rate parameter 
m4 1/min Rate parameter 
m5 min / kg/pmol Rate parameter 
m6 unitless Rate parameter 
HE unitless Hepatic extraction of insulin 
 
 Although the above described dynamic model is made to describe the healthy 
person's glucose-insulin regulatory system, it is also used to describe the IGT, IFG and 
type 2 diabetic metabolism. Dalla Man et al. [33] not only identified the parameters for 
both groups, healthy and type 2 diabetic person, but also minimized structural 
uncertainties of each subsystem. They had a vast data of flux concentrations of 204 
subjects during triple tracer meal tolerance test. Data consist ingested carbohydrates, 
Endogenous Glucose Production (EGP), glucose utilization, insulin secretion, plasma 
glucose concentration and insulin concentration. These were input and output signals 
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for four unit process models; liver, beta cell, muscle and adipose tissue, and 
gastrointestinal track. For instance, liver glucose production was numerically identified 
using EGP as output and plasma glucose and insulin as known inputs. [33] 
 The same meal simulation model was later used as basis for UVA/PADOVA type 1 
diabetes simulator that is included in the first FDA approved in silico population. It 
consists 300 subjects: 100 adults, 100 adolescent and 100 children, and it can be used 
for instance, to test the insulin pumps' control algorithms. Model is also a substitute for 
preclinical trials for certain insulin treatments, including artificial pancreas. [39] 
 Differences compared to previous model are insulin delivery and glucagon 
subsystems. Glucagon can be considered as an opposite to insulin. When plasma 
glucose level is below hypoglycemic limit, glucagon elevates the glucose level. Insulin 
delivery subsystem model depends on the person’s insulin in use. Also, different models 
can be used to describe the delivery. More detailed description of subcutaneous insulin 
kinetics in Section 2.2.3.  
 Even though, above described GRS models explains a wide range of causalities in 
human glucose metabolism, fully explicit model is yet to discover. For instance, acute 
psychotic stress have been shown to have effect on glucose regulatory system and more 
detailed to beta cell function and insulin sensitivity which both links to insulin 
secretion, usage and storage. A clinical global impression (CGI) was used to evaluate 
the level of psychological stress. The relation between CGI score and insulin sensitivity 
is inversely correlated (r = -0.38, P < 0.02) [40]. Thus, model can have many input 
signals. Usual signals are meal; time and carbohydrate amount and insulin; time, dose 
and type. These signals produce the good basis, but as described in Section 1, the 
glucose-insulin balancing equation has many other variables that should be taken into 
consideration. 
2.2.3 Insulin Delivery Models 
Since almost all type 1 diabetics and some of type 2 diabetics are treated with insulin 
injections, maximal GRS models for those includes a subsystem for exogenous insulin 
delivery. Insulin therapy for type 1 diabetics aims to mimic the pattern of endogenous 
insulin secretion present in healthy persons. Yet, human insulin is not commonly used 
in insulin boluses. This is because of absorption of human insulin from subcutaneous 
depot is impeded by the formation of hexameric macromolecules and it has been shown 
that insulin analogues such as insulin lispro has better ability to mimic the physiological 
pattern of insulin secretion. [41] 
Eleven different insulin delivery models were evaluated by M. Wilinska et al. [42]. 
They assessed multiple uncertainties and used experimental data to validate the 
physiological feasibility of parameter estimates. Data were collected from subjects with 
type 1 diabetes whom were treated with continuous subcutaneous insulin infusion with 
insulin lispro (i.e. rapid acting insulin). Their result suggested that the best 
representation was multi-compartment model with two insulin delivery channels, fast 
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and slow. In addition, they had a model which assumed that partition of the injected 
monomeric insulin associates to form dimmers, and thus a state of equilibrium is 
reached between those two. [42] 
 Similar monomeric insulin transport model was also presented by Dalla Man et al. 
[43]. Approach approximates nonmonomeric and monomeric insulin fractions in a 
subcutaneous space as follows: 
 
 
{
 
 
𝑑𝐼𝑠𝑐1(𝑡)
𝑑𝑡
= −(𝑘𝑑 + 𝑘𝑎1) ∗ 𝐼𝑠𝑐1(𝑡) + 𝐼𝑅𝑅(𝑡)
𝑑𝐼𝑠𝑐2(𝑡)
𝑑𝑡
= 𝑘𝑑 ∗ 𝐼𝑠𝑐1(𝑡) − 𝑘𝑎2 ∗ 𝐼𝑠𝑐2(𝑡)
𝑅𝑖(𝑡) = 𝑘𝑎1 ∗ 𝐼𝑠𝑐1(𝑡) + 𝑘𝑎2 ∗ 𝐼𝑠𝑐2(𝑡)
       (2-20) 
 
where Isc1 and Isc2 are the amounts of the nonmonomeric and monomeric insulin, 
respectively. Ri is the rate of appearance of insulin in plasma, kd rate constant of insulin 
dissociation, IRR exogenous insulin infusion rate (i.e. injected insulins as a sum of 
Dirac delta functions), ka1 and ka2 rate constants of nonmonomeric and monomeric 
insulin absorption, respectively. [43] 
2.3 System Dynamics 
System is commonly considered an assemblage of components and dynamics refers to a 
situation which changes with time, so system dynamics basically means time-varying 
behavior of connected components or elements. In this case, dynamics are not just 
mechanical behavior, but also fluid, electrical, thermal, etc. systems. In system 
dynamics, the idea is to deal with entire process with all the causalities included. [44] 
 Human body can be considered to be a system: There are identifiable blocks such 
as organs that affects each other. Although, it is too complicated still to make a model 
describing the whole body, models of different subsystems can be constructed and 
validated against clinical data. For instance, heart's functions can be modeled with 
system dynamics to explain its flow functions or electric functions or combination of 
both. Therefore, it is quite evident method for engineers to describe GRS with system 
dynamics as described in Section 2.2 and in fact, all presented models are dynamic 
systems. 
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3.    MATERIALS AND METHODS  
3.1 Simulation Program 
Since there are wide range of programs to build a dynamic system, a questionnaire was 
made to find the most valuable qualities in simulation software before selecting the 
actual program. In order to get comprehensive results, the questionnaires participants 
were from software, engineering, research and management divisions of Quattro Folia 
Oy. Participants were asked to give a value from 1 to 10 to requirements shown in Table 
3.1., and add other possible requirements if needed. Values were used to calculate 
relative weights in decision matrix. 
 
Table 3.1: Demanded quality and functionality requirements in questionnaire. 
Functional 
requirements Explanation Unit 
Input/Output 
interfaces 
How compatible the software is with 
others 
Number of supported 
formats 
Wide options for 
features 
How many different functions/apps/add-
ons the software offers and how 
complex they are 
Number and 
complexity of 
features 
Easy to learn for 
developer 
How fast you learn to use the software 
and how good manuals and instructions 
you get 
Tester’s opinion 
Good future proofs 
Is the development of the software still 
going 
Amount of new 
versions from 
preceding 5 years 
Low price 
Total cost of ownership Price/User and 
additional costs 
Simple to use and 
maintain 
How good the user interface of software 
is and how easy is to maintain 
Tester’s opinion 
Performance to 
support multiple users 
How much software needs from central 
processing unit (CPU), memory, disk 
space etc. 
Simulation time, 
CPU usage, size of 
the file, etc. 
Modularity 
How easy is to add and remove parts 
from the model 
Possibility to build 
modules 
Testing possibilities 
How easily the model can be tested and 
validated 
Possibility to run in 
script, test features, 
etc. 
Other 
Additional requirement that have not 
been mentioned 
 
 
In order to satisfy the internal customer needs, quality function deployment was 
used to analyze results. Simplified version of house of quality matrix was build. 
Requirements of software were analyzed depending on the measurable unit of the 
requirement. All values were originally between zero to five or normalized to that 
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range. The values were used in decision matrix to calculate the relative weighted results. 
Table 3.2 shows the described decision matrix. 
 
Table 3.2: Decision matrix for simulation program evaluation 
Demanded quality and 
Functional 
requirements 
Relative 
Weight Weight 
Simulation software 
1 2 3 4 
List of internal 
customer needs 
% Values 1-10 Normalized values 0-5 
  Weighted Result Sum Sum Sum Sum 
  Relative Weighted Result % % % % 
 
 The evaluated simulation programs were MathWorks – Simulink 2014a, Ventana 
Systems – Vensim PLE 6.3, Simantics System Dynamics 1.8 and Powersim software – 
Powersim Studio 9 Demo. Although, the programs are popular amongst system 
dynamics, their functionalities, user-interfaces, designed use, modelling methodology, 
etc. vary. Thus, the software meeting Quattro Folia’s internal customer needs and 
quality management requirements could be found. 
 In order to get realistic understanding about the simulation programs, minimal GRS 
model was built with each software before starting to construct the whole body model. 
Two requirements were purely based on tester's opinion; is the software easy to learn 
and simple to use? In addition, the complexity of features and testing possibilities were 
also partly evaluated by tester. 
3.2 Dynamic GRS Model 
3.2.1 General GRS Model 
Based on literature review, the most suitable dynamic GRS model for Quattro Folia's 
indented use was selected. The model was built with the simulation program that got the 
best overall weighted result. Model was constructed for healthy, type 1 and type 2 
diabetic person. All model’s subsystems were validated against clinical data found in 
literature. More about validation process in Section 3.2.2. The validated subsystems 
then were combined in to whole body system. Additional functionalities were also 
introduced based on physiological needs. For instance, in beta-cell function module a 
gain block for remaining insulin production was added in order to get comprehensive 
results.  
 Since diabetics are treated with wide range of therapies, the constructed model 
included also choices at least to the most common therapies. Therefore, alternative 
modules for insulin pump and multiple daily injection (MDI) therapy were built in to 
model. This also meant the implementation of an insulin delivery subsystem. 
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3.2.2 Materials for GRS Model Validation 
Validation of general healthy person model was done against clinical data found in 
literature. Each subsystems output was compared to results from Dalla Man et al. [33], 
where a mixed meal containing 1 ± 0.02 g/kg (x ± SD) of glucose was given to 204 
normal subjects with body weight of 78 ± 1 kg. They measured and estimated various 
fluxes to obtain model-independent results. [33] 
 In particular, each average flux profile; plasma glucose, insulin, EGP, glucose rate 
of appearance, glucose utilization and insulin secretion profiles were compared with the 
simulated results that undergo the same experimental scenario. Thus, 78g of CHO was 
ingested at t = 0 and simulated fluxes were recorded for the next 7 hours. Root mean 
square error (RMSE) and Pearson correlation coefficient (R) were calculated. 
 For insulin delivery subsystem, the validation was done against clinical data from 
Wilinska et al. [42]. They measured plasma insulin concentration from 7 type 1 diabetic 
subjects every 30 minutes after 40g CHO ingestion and injection of individually 
calculated insulin bolus. The continuous insulin infusion rate was 0.86 ± 0.27 IU/h and 
the bolus prior to the meal was 5.95 ± 2.37 IU. Measured insulin concentration was 
compared to simulated results by calculating RMSE and correlation from 12-hour 
period. [42] 
3.2.3 Pilot Data and Individual GRS Model 
A type 1 diabetic did two 7-day pilots. During this period subject had two continuous 
glucose monitors (CGM); Dexcom G4 and Medtronic MiniMed Paradigm Veo. Later is 
a system which includes insulin pump, sensor and MiniLink transmitter that sends the 
information from sensor to insulin pump. However, CGM was not used to control the 
insulin pump and thus, the system was not closed-loop insulin delivery system. CGM 
could only cut off insulin delivery for 2 hours if glucose value was under a preset value. 
Subject reported also blood glucose measurements from fingertip that were used for 
CGM calibrations, meals (carbohydrates ingested) and exercises (duration and level) to 
Quattro Folia's cloud-based personal health record archive.  
 Both weeks were analyzed as an individual events. Figure 3.1 shows the collected 
data; blood glucose values in gray, meals in yellow, insulin in green and exercise in 
orange. In terms of system dynamics and machine learning, the first six days were 
training data and the last day was test data. 
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Figure 3.1: Data collected from a week pilot period. Dashed line represents the division to 
training and test data. Glucose values include continuous glucose monitoring (CGM) and 
self-monitoring of blood glucose (SMBG) values. 
 
 The population based GRS model's parameters were found in literature. They are 
only averages from previous studies and therefore some of them were individually 
updated. For instance, the insulin-to-carbohydrate ratio was calculated with the Rule of 
500 presented in Chapter 2 Equation 2-1.  
Complexity of model affected parameter identification. Since our pilot data were 
collected from routine everyday life, it did not include values such as plasma insulin 
concentration, EGP, etc. Therefore, unit process model and forcing function strategy for 
parameter identification could not be used. Other options such as linearization of the 
problem was discussed with Professor Matti Vilkko from Department of Automation 
Science and Engineering at Tampere University of Technology, but the conclusion was 
that the complexity of model made it impossible without further studies with system 
dynamics. To give an idea of the complexity, a model of an automatic transmission 
controller for vehicle consists of 1 differential equation, 9 algebraic equations and 6 
parameters [45], where the selected combination of models consists of 16 differential 
equations, 14 algebraic equations and 47 parameters. 
 First, the basal level was approximated to correspond with the subject’s basal level. 
An independent algorithm estimated the base level of the subject’s blood glucose and 
then set the parameter kp1 in EGP subsystem to correspond the subject’s basal level. 
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Figure 3.2: Decision chart of adaptive parameter identification algorithm for steady state  
 
The parameter identification to find the steady state was made with fine tuning with 
simple algorithm and repeated simulations as described in Figure 3.2. All the input 
parameters were constant during the following method. First, the reference standard 
deviation (SD) was calculated. Next, the basal levels of the following parameters; Il, Ip, 
Icon, Gp, Gt, EGP, Isc1 and Isc2 were adjusted, and then the previous SD was compared to 
the latest results. If SD was reduced, values were adjusted again and another simulation 
was made. This was repeated until the SD was same or greater as previous and then the 
previous parameters were saved. If the first calculated SD was increased, the starting 
values were adjusted to another direction and the best fitting value was identified with 
same procedure. 
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Figure 3.3: Decision chart of adaptive parameter identification algorithm for any 
parameter or parameters. 
 
Similar adaptive parameter identification algorithm as the algorithm for steady 
state was used to adjust any parameter or parameters. Figure 3.3 shows the algorithm’s 
decision chart. First, the reference RMSE and correlation were calculated. Next, the 
parameter was adjusted, and then the previous RMSE and sometimes correlation were 
compared to the latest results. If RMSE was reduced, values were adjusted again and 
another simulation was made. This was repeated until the RMSE was greater and then 
the previous parameters were saved. If the first calculated RMSE was increased, the 
starting values were adjusted to another direction and the best fitting value was 
identified with same procedure. In addition, if the improvement in RMSE was not 
significant, the correlation was also evaluated. Based on the change in correlation, 
parameters were adjusted again or previous parameters were saved.  
Insulin related actions were adjusted with four measurable parameters; amplitude, 
onset time, peak time and duration. The last three are parameters which averages insulin 
manufacturers report but can vary between users. Amplitude was used to adjust hepatic 
and peripheral insulin sensitivity, kp3 and Vmx, respectively. Onset time was sought with 
independent algorithm which calculated difference between time of administered insulin 
and time when glucose change rate went to negative. This was done in sections where 
bolus was taken to correct too high blood glucose and there was no upcoming meals. 
When bolus and meal were timed at the same time, the peak time of insulin bolus was 
analyzed with an algorithm that identified the peak from CGM data and sought 
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matching peak from simulated blood glucose data. The time differences between these 
peaks were used to adjust the insulin peak time. Last, the insulin duration was adjusted 
to match the active time of insulin bolus, thus the time when glucose change rate was 
close to zero after the peak. Average insulin active times can be also found in Figure 
2.2. 
Since above represented algorithms are based on correlation and RMSE, the 
simulation output fit to CGM data was evaluated with R to RMSE ratio that was 
designed to be used in this study only. Higher the ratio was, better the fit was. This also 
proofs the concept of algorithms, if parameter identifications steps are improving the 
training accuracy. Ratio was only use to compare simulation steps. 
  
31 
 
4. RESULTS 
4.1 Comparison of Simulation Programs 
Figure 4.1 shows the minimal GRS model build with Simulink 2014b Academic 
license. The model had to be constructed from single blocks such as integrator, thus it 
was logical to build the model from equations, but at the same time understanding of 
causalities between compartments got more difficult to perceive. 
 
Figure 4.1: Simple glucose regulatory system model build with Simulink 
 
 Simulink’s manuals, instructions and helps are well documented and they were 
easy to understand. Because Simulink is widely used, instructional sites and video 
tutorials can also be found. Simulink could not be used without MATLAB and this 
offered multiple opportunities: Different input and output formats were supported; the 
simulation could be run in script, thus testing, multiple user support and modularity 
were improved. 
 MathWorks have released a new version of MATLAB and Simulink twice-a-year 
and there has been significant improvements included. For instance, in 2014b version 
has been implemented a simulation data inspector which enabled the recording of 
different signals between the simulations. Therefore, it was easy to compare the signals 
when developing the model functionalities and modules.  
 As mentioned above, Simulink is a MATLAB add-on, therefore the price of 
Simulink includes also MATLAB’s price. In addition, Simulink product family includes 
add-ons also for real-time simulation, testing, verification, validation, etc. These are 
individually sold extras that are not included the evaluated price. 
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 Second tested simulation software was Ventana Systems Vensim PLE 6.3. Program 
was easy to use and the minimal GRS model was fast to build. Figure 4.2 shows the 
model from which the causalities of GRS are simple to understand. The user interface 
was simple and required only a little time to understand.  
 
Figure 4.2: Simple glucose regulatory system model build with Vensim 
 
Import and export formats were limited, thus interfaces with other programs was 
poor compared to Simulink. Although, worth mentioning is that commercial license 
offered better data connectivity. Ventana Systems has only released four version from 
preceding 5 years and there has not been any major improvements. Model could not be 
run in script or loop which made it hard to test and especially, would have made it hard 
to implement the model for multiple users. Also, there was no possibility to build 
individual modules. Although, the tested software was a free version, it lacked 
significantly in needed requirements.  
 Next tested software was Simantics which is an open platform for modelling and 
simulations. Its performance should be excellent with data triple engine on the server 
side. At the same time it was developed to be scalable and reliable which were 
definitely an advantages for Quattro Folia’s planned use of the model. The build GRS 
model in Figure 4.3 resembles the model build with Vensim in Figure 4.2, thus the 
modelling view and structures are similar to Vensim. Yet, Simantics was not as easy to 
learn and simplicity of the program was the worst of all four. For instance, the end-user 
wiki was clumsy to use and it took a lot of time to start to build the actual model. If 
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compared to Simulink which was also hard to get into, the manuals and instructions of 
Simantics were not as explicit as in Simulink. 
 
Figure 4.3: Simple glucose regulatory system model build with Simantics 
 
 The amount of features was low in Simantics and testing features or possibility to 
run in a script were missing. Also the modularity and compatibility to other programs or 
formats were weak. The best thing in Simantics was the price. It was free. This also 
raises questions about the future developments and certainty of the new versions or 
updates. Nevertheless, if software is stable already and its functionalities are meeting 
the Quattro Folia’s needs, it could be used years even without updates. 
 The last tested simulation software was Powersim Studio 9 Demo which user 
interface was quite pleasant. It was easy to get into and the basic features were simple to 
find. The build model shown in Figure 4.4 looks similar to Vensim and Simantics. 
Unlike other programs, Powersim offered possibility to the build model as equations 
which was a great way for understanding system dynamics and validating that the built 
model was as it was in equations.  
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Figure 4.4: Simple glucose regulatory system model build with Powersim 
 
 But as Vensim and Simantics, Powersim lacked in amount of supported formats 
and its testing possibilities and multiple user support were weak, thus it did not have 
possibility to run in script nor it could be exported to other programs as an independent 
function or block. Also, Powersim was the most expensive program of these four and it 
has not have as many new releases or updates from preceding 5 years as has others. 
 
Table 4.1: Decision matrix for evaluating simulation programs. Weights are calculated 
according to the results of questionnaire. Bolded values are the best in each row. *Row 
values are normalized between 0-5. 
Demanded quality and 
Functional requirements 
Relative 
Weight Weight 
Simulation software 
Simulink Vensim Simantics Powersim 
Input/Output interfaces* 10.43 6.80 5.0 0.2 0.0 0.4 
Wide options for features 10.12 6.60 5.0 2.5 0.0 2.5 
Easy to learn for developer 9.82 6.40 1.0 5.0 4.0 4.0 
Good future proofs* 11.66 7.60 5.0 0.7 2.1 0.0 
Low price* 11.96 7.80 0.0 0.0 5.0 0.0 
Simple to use and maintain 10.12 6.60 2.0 3.0 1.0 3.0 
Performance to support 
simultaneous users* 10.43 6.80 5.0 0.5 0.0 0.0 
Modularity 12.88 8.40 2.0 3.0 3.0 3.0 
Testing possibilities 12.58 8.20 5.0 2.0 1.0 3.0 
 
Weight 216.4 120.4 120.9 114.3 
 
Relative Weight 37.83 21.05 21.13 19.99 
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Table 4.1 shows the results of decision matrix. Simulink was superior at 
input/output interfaces and multiple user support. It offered wide range of import and 
export options and possibility to run in script makes testing possibilities simpler. Also 
options for features, future proofs and testing possibilities were better than in other 
evaluated programs. Furthermore, Simulink had the highest relative weight. 
4.2 General Dynamic GRS Model 
The general GRS model was selected based on literature review. One model was 
superior in terms of validation. Dalla Man et al. [33] used wide range of flux data to 
parameter identification. As mentioned in Section 2.2.2, they had data from 204 
subjects and the unit process model consist four compartments; liver, gastrointestinal 
track, muscle and adipose tissue and beta cell. Model was also used basis for the first 
Food and Drug Administration (FDA) approved in silico population. Therefore, the first 
build model was same as shown in Figure 2.7 and described in Equations 2-11 to 2-19. 
 
Figure 4.5: Gastro-intestinal track subsystem modeled with Simulink and described in 
Equation 2-11. Gray block, k_empt, is another subsystem that describes the nonlinear 
function of gastric emptying. 
 
 For the sake of space, here is only shown one example how the subsystems are 
modeled with Simulink. Figure 4.5 shows how the dynamic Equation 2-11 is 
represented in Simulink. Input signal is the amount of ingested glucose D at time t. 
After various grinding and absorption processes in stomach and guts the subsystem 
output, glucose rate of appearance in plasma, is generated and added to plasma glucose 
compartment in glucose subsystem. Above described subsystem is the gastrointestinal 
track in Figure 4.8. 
 Validation was done against clinical data and Figure 4.6 shows the results from 
literature compared to the model’s subsystem outputs. The gray are represents mean ± 1 
standard deviation (STD) and as can be seen in the Figure, the inter-subject variability is 
high especially in plasma insulin concentration and in endogenous glucose production.  
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Error with the clinical averages and simulated data is shown in Table 4.2. RMSE is 
relatively small and correlations are very high in each of the six examined signals. Here, 
plasma glucose unit is now in mg/dl in order to compare the results and superimpose the 
figure. Later, the plasma glucose unit is changed to mmol/L that is the SI unit. 
 
Table 4.2: Root mean square error (RMSE) and correlation (R) between simulated and 
clinical average data from [33]. 
Signal (unit) RMSE R 
Plasma Glucose (mg/dl) 6.46 0.99 
Plasma Insulin (pmol/L) 54.18 0.97 
EGP (mg/kg/min) 0.90 0.95 
Rate of Appearance (mg/kg/min) 1.33 0.81 
Glucose Utilization (mg/kg/min) 0.32 0.86 
Insulin Secretion (pmol/kg/min) 0.97 0.97 
Figure 4.6: Simulation data (in red) superimposed on clinical data from 204 subjects 
(gray area represents mean ± 1 STD range). [33, p. 1741] 
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The same GRS model be used to describe those type 2 diabetics who do not use 
additional insulin. Average parameters are in Appendix I. For insulin treated diabetics, 
an insulin delivery subsystem had to be included. Here, a two-compartment 
subcutaneous insulin transport model described in Equation 2-20, was used, because the 
parameter identification was done with a largest amount of subjects, thus statistically it 
was the most relevant. In addition, insulin injection had three options: bolus, basal or 
continuous insulin infusion via insulin pump. Yet, the option with insulin pump only 
enabled open-loop and not closed-loop control algorithm. Thus, there was no feedback 
loop to control the insulin pump’s insulin delivery. In addition, the remaining insulin 
production can be adjusted, but with type 1 diabetics it is usually zero. 
 
Figure 4.7: Simulation data superimposed on clinical plasma insulin (Ip) concentration 
from 7 type 1 diabetic subjects. Black circles are mean values with ±1 STD. [42, p. 7] 
 
 Insulin delivery model was also validated against clinical data. Figure 4.7 shows 
the comparison with plasma insulin concentration after the meal and simulated insulin 
concentration (in red) with the same ingested CHO and injected bolus. In addition, 
simulation was also done with ±1 STD error in continuous insulin infusion and prandial 
bolus. These are plotted in dashed blue line. RMSE and correlation between simulated 
and clinical average data were 41.21 pmol/L and 0.97, respectively. 
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Figure 4.8: Dalla Man et al. glucose regulatory model with the insulin delivery model 
added. Glucose related parts are in blue and insulin related in red. 
 
All validated subsystems were combined to the GRS model that is shown in Figure 
4.8 which is similar to Figure 2.8. Difference is an insulin delivery subsystem. Transfer 
and controlling signals are marked in solid and dashed lines, respectively. Red 
represents insulin related actions and blue glucose related. The exogenous insulin input 
with insulin pump is a sum of continuous insulin infusion and boluses. For MDI 
therapy, the exogenous insulin has two signals; one for basal and one for bolus 
injections. Both of the signals depends on the type of administered insulin, thus the 
onset, peak and acting time can be adjusted.  
4.3 Individual GRS Model and Parameter Identification 
Collected data from pilot weeks 1 and 2 to consist; 20 and 14 meals, 36 and 33 
bolus, and 34 and 28 SMBG measurements, respectively. RMSE and correlation of two 
glucose profiles; mean of CGMs and simulated blood glucose, are shown in Table 4.3 
and includes training and test results for both of the individual pilot weeks.  
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Table 4.3: Simulation error and correlation for two independent pilot weeks. Weeks are 
divided into training (1st-6th day) and test data (7th day). 
  Week 1 Week 2 
 
Train Test Train Test 
Simulation 
RMSE (mmol/L)  R 
RMSE 
(mmol/L) R 
RMSE 
(mmol/L) R 
RMSE 
(mmol/L) R 
Original 7.716 0.170 9.066 -0.173 9.360 0.019 10.559 0.418 
1 4.683 0.195 5.507 0.060 5.457 -0.010 5.216 0.560 
2 4.380 0.204 3.630 0.306 4.786 -0.028 3.727 0.466 
3 4.229 0.220 3.964 0.293 4.389 -0.044 2.825 0.446 
4 4.141 0.226 3.311 0.277 4.715 0.011 2.593 0.587 
5 3.992 0.245 3.542 0.185 4.612 0.003 2.604 0.571 
6 3.744 0.285 3.640 0.241 4.520 0.019 2.631 0.527 
7 3.646 0.285 2.809 0.292 4.322 0.011 2.761 0.587 
 
Figures 4.9 and 4.10 shows model input parameters and simulated blood glucose 
(simBG) in time. Input parameters were meals, bolus and basal insulins. Note that 
ingested carbohydrates are divided by 10 to fit the values in the same axis. Subplot A is 
the initial simulation without any parameter adjustment and C the best fit. Test data, 
right from dashed vertical line, shows the 24-hour blood glucose prediction. In addition, 
SMBG measurements are plotted also. 
 
 
Figure 4.9: Pilot week 1 recorded and simulated data. Plots from top to down: A is the 
initial simulation without any parameter adjustment; B is simulation 1, where the first 
parameter kp1 is adjusted and steady state sought by adjusting basal values of Il, Ip, Icon, 
Gp, Gt, EGP, Isc1 and Isc2; C is the last simulation number 7, thus the best parameter 
identification achieved. 
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Figure 4.10: Pilot week 2 recorded and simulated data. Plots from top to down: A is the 
initial simulation without any parameter adjustment; B is simulation 1, where the first 
parameter kp1 is adjusted and steady state sought by adjusting basal values of Il, Ip, Icon, 
Gp, Gt, EGP, Isc1 and Isc2; C is the last simulation number 7, thus the best parameter 
identification achieved.  
 
During the parameter identifications, 7 steps was used to obtain the best fit. In total 
of 22 parameters were adjusted. For both weeks those parameters were kp1, Il, Ip, Icon, 
Gp, Gt, EGP, Isc1, Isc2, BW, remaining insulin production, TDI, m2, kp2, kp3, Km, p2U, 
ke1 and ke2 and insulin onset time. For first week also parameter ka1 was adjusted. 
Some of the parameters were adjusted in multiple steps to obtain the best result. All the 
adjusted parameters were verified to be within physiological limits. For instance, there 
could not be negative values for insulin sensitivity as in Bergman’s model. Other 
parameters were kept untouched. For instance, changing of insulin related parameters; 
amplitude, peak time and duration, with the proposed algorithms did not improve test 
results. 
 
Figure 4.11: Correlation (R) divided by RMSE after parameter identification steps. Solid 
and dashed line represents training and test data, respectively. 
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  Figure 4.11 shows the improvement of R to RMSE ratio during the training and 
testing period. During the training period the ratio should be improved constantly in 
order to get better parameter identification. Testing period is only allowed to use as an 
independent period, thus it is not known during the training period but only predicted 
after the training period.  
 
  
42 
 
5.    DISCUSSION AND CONCLUSION 
Based on questionnaire, Quattro Folia Oy demanded simulation software that was easy 
to test and had good modularity. They also required low price and good future proofs. 
Minimal GRS model was built with four programs and Simulink had the highest relative 
weight according to decision matrix in Table 4.3, thus it was the best program for 
Quattro Folia’s criterions and therefore the maximal GRS model was built with it. One 
of the key factors was the testing possibilities that were the best in Simulink. In 
addition, the program enables comprehensive understanding of system dynamics, 
whereas other simulation programs are easier to learn and use, but lack in testing, future 
proofs and features. 
Maximal GRS model was then built and validated with Simulink. Table 4.2 shows 
the simulated general GRS model correspond with the clinical data; decent RMSEs and 
very high correlations. Only the glucose rate of appearance exceeded the 1 STD limit, 
but this was only after 6 hours after the meal. Similarly, insulin delivery model was 
shown to correspond with clinical data in Figure 4.7. RMSE was in acceptable range 
and correlations was very high. Only a small time difference can be seen at the start of 
simulation, since insulin delivery system here included insulin onset time which was 
based on rapid acting insulin average, thus delay was initially 15 minutes. Apart from 
first 20 minutes, plasma insulin concentration falls within the 1 STD limits. Also, 
insulin delivery system was made for MDI and insulin pump therapy. 
For first pilot week retrospective analyses, Table 4.3 shows the improvement of 
both RMSE and R during the parameter identification (i.e. training period). The same 
continuous improvement can be seen in Figure 4.11 where the R to RMSE ratio 
increases constantly and the best test results also was obtained with the best parameter 
identification results. For second week the lack of input data, particularly meal data, 
resulted in low correlation during the training. Although, test data in Figure 4.11 shows 
improved R to RMSE ratio, the result are not applicable. Figure 4.10 part C shows how 
the variance of simulated blood glucose has decreased which ultimately led almost 
constant simulated blood glucose. User reported only 14 meals in seven days and in 
three of those days had only a single meal. In order to get realistic parameter 
identification results, model needs to have input data which elevates and reduces the 
blood glucose, thus input data must include both meals and insulins, respectively. 
One solution could be to have a shorter pilot period. Model parameter identification 
could be done in one day or in 7 hours as Dalla Man et al. did [33] and then have a test 
period of the same length. This way even amount of ingested carbohydrates could be 
more accurate, since in this case it was based only on user’s estimation. The exact 
glycemic load of meal could be predefined and have even the blood glucose 
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measurements done with finger stick measurements, which brings us to the next error in 
the setup. 
Training period assumes that the reference CGM signal is without an error, thus the 
best possible simulated blood glucose can be as good as the CGM blood glucose 
estimation is. Since CGMs has their own independent algorithms to estimate blood 
glucose based on glucose measured from interstitial fluid, reference CGM signal here 
was chosen to be the mean of both devices.  
Yet, there has been recent report showing that CGM results could be improved in 
retrospective [46]. For future development, an implementation of this or similar method 
would be direct improvement to simulation results. Also, the better parameter 
identification itself would improve the results. This should be discussed further with 
system dynamics experts such as Professor Matti Vilkko.  
Since the model does not incorporate intrasubject variability of parameters such as 
insulin sensitivity, future physiological development ideas are to include the dawn 
phenomenon and high blood glucose effect on insulin sensitivity discussed in Section 
2.1.3. Latter especially in this case could have improved the results significantly, since 
the pilot user was relatively long periods over high blood glucose limit (i.e. over 12 
mmol/L). This can be observed from Figures 4.9 and 4.10. Also, the effects of stress 
that were discussed in the end of Section 2.2.2 would be relevant idea to take into 
account and furthermore, implement in the model. Unfortunately, an explicit model 
describing the effects of stress to GRS has not yet presented. Similar to stress, the 
effects of exercise should be included to model also. Recent publication have shown a 
promising results how to implement exercise subsystem to GRS model [47], and 
actually it is the next subsystem to be implemented in the model.  
 In conclusion, the simulation program best meeting Quattro Folia’s criterions was 
Simulink and maximal GRS model was built and validated with it. General GRS model 
was then adapted to correspond a pilot user’s physiological values. Parameter 
identification worked with extensive and intact input data, and blood glucose prediction 
for 24 hours showed low correlation and relatively small error for the test period. Yet, 
statistically more reliable results could be obtained with greater test subject amount.  
Model have possible usages from in silico testing to teaching causalities for diabetics, 
thus it is useful for research, validation and educational purposes.  
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APPENDIX 1: Parameters for GRS Model from 
Literature 
 
Part 1: Average parameters for GRS model [33] 
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Part 2: Insulin delivery subsystem average parameters[48] 
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APPENDIX 2: Full GRS Simulink Model  
 
Screen capture 1: Model view at the top layer 
 
 
Screen capture 2: Subsystem HUMAN at second layer of the model 
 
Screen capture 3: Subsystem GASTROINTESTINAL TRACK at third layer of the model 
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Screen capture 4: Subsystem k_empt at fourth layer of the model 
 
 
Screen capture 5: Subsystem LIVER at third layer of the model 
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Screen capture 6: Subsystem GLUCOSE at third layer of the model 
 
 
Screen capture 7: Subsystem BETA-CELL at third layer of the model 
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Screen capture 8: Subsystem INSULIN at third layer of the model 
 
Screen capture 9: Subsystem Hepatic extraction of Insulin at fourth layer of the model 
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Screen capture 10: Subsystem INSULIN DELIVERY at third layer of the model 
